Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVT 1075

Next Previous
Drug Profile

MVT 1075

Alternative Names: 177Lu Human Monoclonal Antibody 5B1; 177Lu- CHX-A″-DTPA-HuMAb-5B1; 177Lu-DTPA-HuMab-5B; 90Y- CHX-A″-DTPA-HuMAb-5B1; HuMab 5B1 radioimmunotherapy agent - MabVax; HuMab-5B1 conjugated Actinium225-radioimmunotherapy agent; MVT 1916; MVT-1075; radiolabeled HuMab 5B1 antibody - MabVax

Latest Information Update: 05 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 05 May 2023 CTP push 700276997: KDM updated, phase termination HE added, NDR retained as such as no development has been reported since 5 years
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top